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Abstract: A novel brominated alkaloid, Securidine A, was isolated from the cold water marine
bryozoan Securiflustra securifrons. Securidine A was isolated using semi-preparative HPLC, and
the structure was elucidated by spectroscopic methods. The isolated Securidine A was tested for
cytotoxic, antibacterial, and anti-diabetic activities as well as for its potential for inhibition of biofilm
formation. No significant biological activity was observed in the applied bioassays, thus expanded
bioactivity profiling is required, in order to reveal any potential applications for Securidine A.
Keywords: secondary metabolites; marine invertebrates; marine bryozoans; Securiflustra securifrons;
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1. Introduction
Marine organisms are considered to be a rich source for natural products, and currently almost
50,000 marine natural products are reported in the Dictionary of Marine Natural Products [1].
A statistical analysis of marine natural products discovered between 1985 and 2008 estimates that
approximately 75% of the compounds are isolated from sessile and soft-bodied invertebrates including
sponges, ascidians, cnidarians, mollusks and bryozoans [2,3]. In order to protect themselves from
predators and to compete for space and food, many invertebrates have evolved the ability to produce
secondary metabolites as a chemical defense, which increase their ability to survive, grow, and
reproduce [4,5]. Bryozoans, or moss animals, are aquatic invertebrates that belong to the phylum
Bryozoa (Polyzoa). They are sedentary and filter feeders. These colonial organisms consist of tiny
intercommunicating individuals called zooids [6]. Bryozoans are widely distributed in tropical and
temperate marine waters [7], and are common fouling organisms on marine substrates [6]. The phylum
consists of 3 classes, 4 orders, 187 families, and 808 genera, and approximately 8000 species are
described, most of them are observed in marine habitats [8,9]. Marine bryozoans are known to produce
a significant number of biologically active secondary metabolites, including macrolides, alkaloids,
sterols, and heteroatom-containing compounds [3,10] that possess antitumor [11], antibacterial [12,13],
and muscle relaxant activities [14]. The well-known bioactive compound bryostatin 1 is a macrolide
isolated from the marine bryozoan Bugula neritina, and it is proven to be an antineoplastic agent [15].
Secondary metabolites isolated from marine bryozoans have been extensively reviewed [6,8,16,17].
In the present study, we isolated the novel mono brominated tyrosine derivative Securidine
A (1) from the marine bryozoan Securiflustra securifrons. S. securifrons (Pallas, 1766) is a temperate
and subtidal species abundant in the North Sea [18,19], and the encrusting basal portion of the
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colonies are attached to hard substrates such as stones and shells. In previous reports, seven
halogenated indole-imidazole alkaloids, Securamines A–G and Securines A and B (obtained by
dissolving Securamines A and B in DMSO-d6), have been isolated from S. securifrons, but no biological
activities were recorded for any of these compounds. The halogenated Securamines A–G (Figure 1)
differ from each other by the presence and absence of a bromine substitution or a number of bromine
substitutions in the benzene ring. [20,21]. These compounds are structurally similar to chartellines
A–C and chartellamides A and B, isolated from another marine bryozoan Chartella papyracea. Both
species belong to the Flustridae family (Order: Cheilostomata). Many of the Cheilostome bryozoans
including S. securifrons, C. papyracea, and Flustra foliacea are producing indole alkaloids and brominated
alkaloids [12,20–32]. However, the isolated new brominated alkaloid, Securidine A (1) is a novel
structure (Figure 1), which is not structurally similar to any other listed compounds of S. securifrons.
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2. Results and Discussion
The marine bryozoan S. securifrons was collected in April 2014 in the North Sea. Securidine A (1)
was isolated from the aqueous extract of S. securifrons through stepwise fractionation. The lyophilized
animal material was ground and extracted with ultrapure water. The freeze-dried aqueous extract was
pre-fractionated using column chromatography with a Biotage SP24 HPFC flash purification system.
The extract was eluted with a gradient of H2O/CH3OH/CH3-CO-CH3 and the fractions were assayed
for cytotoxicity against melanoma (A2058) and colon adenocarcinoma (HT29) cell lines using an MTS
based anticancer assay. Flash fractions four and five showed cytotoxic activity. UPLC-HR-MS analysis
of these fractions, followed by isotopic pattern examination of the eluting compounds, revealed the
presence of a mono brominated compound. For the isolation, the aqueous extract was injected onto
semi-preparative RP-HPLC C18 column and Securidine A (1) was eluted with a 10 minutes gradient,
changing from 10% to 40% CH3CN over 10 minutes. For the second purification step, a Phenyl-Hexyl
prep HPLC column was used with a 10 min gradient, changing from 10% to 34% CH3CN.
The HR-MS analysis suggested that Securidine A (1) contained a bromine. The molecular formula
was determined to be C14H21BrN4O2, corresponding to the protonated molecular peak at m/z 357.0858
([M + H]+, calculated m/z 357.0926), suggesting six degrees of unsaturation. A database search
indicated that the isolated compound was novel, and its structure was solved based on a number of
1D and 2D NMR experiments.
Interpretation of the available 1D 1H (presat, 1DNOE and excitation sculpting), 1D 13C,
HMBC, ME-HSQC, H2BC, COSY, and ROESY (Supplementary materials Figures S1 to S6) led to
an unambiguous structural elucidation of 1. Examination and comparison of the 1D 13C, HSQC,
and HMBC showed that 1 had 14 carbons consisting of one methyl group, five methylenes, three
methines, and five quaternary carbon atoms. Two 1H resonances, H-10 and H-15, were identified
as NH groups based on the absence of any 1JCH, broadened line widths and deshielded chemical
shifts. Three methines indicated the presence of a disubstituted phenyl ring attached to the main chain.
The methyl group protons (δH 3.84) showed HMBC correlation to the quaternary C-2 (δC 156.2) as
well as ROESY correlation to the H-3 (δH 6.96) methine proton. The relatively deshielded chemical
shift value of the methyl protons (δH 3.84) was assigned as the protons of a methoxy group. The high
chemical shift value of C-2 (δC 156.2) further confirmed this. COSY and ROESY correlations between
H-3 (δH 6.96) and H-4 (δH 7.22) as well as a shared coupling constant of 8.6 between the two, places C-3
and C-4 next to each other. Additionally, the H-3 methine showed HMBC correlation to a halogenated
quaternary carbon (C-5, δC 112.2), the quaternary C-7, (δC 130.5) as well as to the final methine carbon
(C-6, δC 134.5). The distinction between C-7 and C-5 was made based on their chemical shift values
and a 2JCH from C-5 to H-6, which is commonly observed from halogenated carbons but not from
carbons in phenyl rings further away from heteroatoms. The H-8 (δH 3.41) methylene showed ROESY
and HMBC correlations to the protons and carbons in position 4 (δH 7.22, δC 130.2) and 6 (δH 7.47,
δC 134.5), placing it in ortho position to C-4 and C-6 in the phenyl ring. The phenyl group was
thus methoxy-substituted in the para position and brominated in the meta position, while and the
main chain of the molecule was attached to C-7. The H-8 (δH 3.41) protons further showed a HMBC
correlation to a deshielded quaternary carbon (C-9, δC 173.7), characteristic for a carbonyl carbon.
HMBC correlations were observed to H-10 (δH 8.20) from C-9 and to H-10 from C-11 (δC 39.8). COSY
and ROESY correlations were observed between the methylene groups in the 11 (δH 3.20, δC 39.8)
and 12 positions (δH 1.56, δC 27.5). The same correlations were observed between the methylene
groups in position 13 (δH 1.55, δC 27.0) and 14 (δH 3.16, δC 42.0). The methylene groups in the 12 and
13 position were near isochronous, but could be distinguished by their respective couplings to H-11
and H-14 in H2BC and COSY. H-14 further correlated with the quaternary C-16 (δC 158.8) in HMBC
spectra. H-13 (δH 1.55) and H-14 (δH 3.16) both showed ROESY correlations to H-15 (δH 7.57). This,
in addition to a COSY correlation between H-14 and H-15, places a NH-group in the 15 position. Thus,
the remaining part of the chemical formula was N2H3, leaving the only possible structural solution to
be the attachment of an NH- and an NH2- group to C-16. The deshielded shift value of C-16 (δC 158.8)
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was in good agreement with this conclusion (Table 1). Selected 2D correlations utilized in determining
the structure of 1 are shown in Figure 2. The compound was named Securidine A.
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Table 1. NMR spectroscopic data (600 Hz, methanol-d3).
Position δC, Type δH (J in Hz) COSY 1H, 13C-HMBC b 1H, 13C H2BC ROESY
1 56.6, CH3 3.84, s 2 3
2 156.2, C
3 113.1, CH 6.96, d (8.6) 4 2,5,7 4 1,4
4 130.2, CH 7.22, dd (8.6, 2.3) 3,6 2,3,6,8 3 3,8
5 112.2, C
6 134.5, CH 7.47, d (2.3) 4 2,4,5,8 8
7 130.5, C
8 42.4, CH2 3.41, s 4,6,9 4,6,10
9 173.7, C
10 8.20, s 11 9,11 11 8,11,12 w
11 39.8, CH 2 3.20, q (6.4) 10,12 9,(12/13) d 12 10,12
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a 1H 1D, 13C, 1H, 1H-COSY, 1H,13C-HMBC (full and band selective) spectra are included in the supplementary data,
Figures S1–S6 (Supplementary materials). b 1H 1D, 13C-HMBC correlations are from the proton(s) stated to the
indicated carbon; c Overlapping and/or broadened peaks impeding complete multiplet analysis. Chemical shift
extracted from 1H, 13C-HSQC, 1H, 13C-HMBC and/or 1H, 13C-H2BC; d ambiguous correlations in HMBC, C12 and
C13 assignment based on H2BC correlations (Figure S4); w Weak correlations.
Bioactivity
The pure Securidine A (1) was ev luated for its biologic l activity in a selection of bioassays
including anti-cancer and anti-bacterial activity, inhibition of protein tyrosine phosphatase 1B (PTP-1B)
for anti-diabetic activity, as well as for inhibition of biofilm formation.
Securidine A (1) was assessed for its cytotoxicity against three cancer cell lines (A2058 melanoma,
HT29 colon adenocarcinoma and MCF7 breast carcinoma) by the MTS method, since flash fractions of
the extract from S. securifrons showed anticancer activity against A2058 melanoma and HT29 colon
adenocarcinoma cancer cell lines in the MabCent screening program [33]. However, the isolated
compound, Securidine A (1), did not show any significant activity against the cancer cell lines at
50 µM (17.87 µg/mL) or 100 µM (37.73 µg/mL). Securidine A (1) was also tested for its antibacterial
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activity, and no activity was seen against Staphyloccoccus aureus, Escherichia coli, Enterococcus faecalis,
Pseudomonas aeruginosa, or Streptococcus agalactiae.
Securidine A (1) is a brominated tyrosine derivative. It is structurally related to two other
brominated tyrosine derivatives, Pulmonarin B (2) and Synoxazolidinone B (3) (Figure 3), both isolated
from the sub-Arctic ascidian Synoicum pulmonaria [34,35]. Pulmonarin B (2) contains a quaternary
ammonium group in the side-chain instead of the guanidine group of Securidine A (1) and Pulmonarin
B (2) did not have any antibiotic or cytotoxic activity. Both Securidine A (1) and Synoxazolidinone B
(3) have a guanidine group in the side chain, but Synoxazolidinone B (3) has a central 4-oxazolidinone
core, linking a di-brominated tyrosine derivative to an arginine [36]. Synoxazolidinone B (3) is active
against the Gram-positive bacteria, methicillin resistant S. aureus. Macherla et al. suggested that a
4-oxazolidinone core is a good pharmacophore for antibacterial activity [36]. The difference between
Securidine A (1) and Synoxazolidinone B (3) in activity against bacteria might thus be explained by the
lack of a central 4-oxazolidinone core in Securidine A (1). Moreover, most of the antimicrobial peptides
or alkaloids are amphipathic molecules, including Synoxazolidinone B, which displays two cationic
groups and two bulky lipophilic groups in order to fulfill the structural requirements of antibacterial
activity [37–39]. A study of the pharmacophore of small antibacterial peptides demonstrated that
one cationic group as well as a minimum of two bulky groups were required for activity against
Gram-positive staphylococci [40].
Molecules 2017, 22, 1236  5 of 11 
 
Securidine A (1) was assessed for its cytotoxicity against three cancer cell lines (A2058 
melanoma, HT29 colon adenocarcinoma and MCF7 breast carcinoma) by the MTS method, since flash 
fractions of the extract from S. securifrons showed anticancer activity against A2058 melanoma and 
HT29 colon adenocarcinoma cancer cell lines in the MabCent screening program [33]. However, the 
isolated compound, Securidine A (1), did not show any significant activity against the cancer cell 
lines at 50 µM (17.87 µg/mL) or 100 µM (37.73 µg/mL). Securidine A (1) was also tested for its 
antibacterial activity, and no activity was seen against Staphyloccoccus aureus, Escherichia coli, 
Enterococcus faecalis, Pseudomonas aeruginosa, or Streptococcus agalactiae. 
Securidine A (1) is a brominated tyrosine derivative. It is structurally related to two other 
brominated tyrosine derivatives, Pulmonarin B (2) and Synoxazolidinone B (3) (Figure 3), both 
isolated from the sub-Arctic ascidian Synoicum pulmonaria [34,35]. Pulmonarin B (2) contains a 
quaternary ammonium group in the side-chain instead of the guanidine group of Securidine A (1) 
and Pulmonarin B (2) did not have any antibiotic r cytotoxic activity. Both Securidine A (1) a d 
Synoxazolidinone B (3) have a guanidine group in the side chain, but Synoxazolidinone B (3) h s a 
ce tral 4-ox zolidinone core, l nking a di-brominated tyrosine derivative to an arginin  [36]. 
Syn xazolidinone B (3) is active against t e Gram-positive b cteria, methicillin res stant S. aureus. 
Macherla et al. suggested that a 4-oxazolidinone core is a good pharmacop ore for antibacterial 
activity [36]. The difference between Securidine A (1) and Synoxazolidinone B (3) in activity against 
bacteria might thus be explained by the lack of a central 4-oxazolidinone core in Securidine A (1). 
Moreover, most of the antimicrobial peptides or alkaloids are amphipathic molecules, including 
Synoxazolidinone B, which displays two cationic groups and two bulky lipophilic groups in order to 
fulfill the structural requirements of antibacterial activity [37–39]. A study of the pharmacophore of 
small antibacterial peptides demonstrated that one cationic group as well as a minimum of two bulky 
groups were required for activity against Gram-positive staphylococci [40]. 
 
Figure 3. The structurally related compounds Securidine A (1), Pulmonarin (2), and Synoxazolidinone 
B (3). 
The effect of Securidine A (1) against PTP-1B was also examined, since PTP-1B is regarded as a 
promising target for the treatment of diabetes [41]. However, no inhibition of PTP-1B was observed 
at 50 µM or 100 µM. Many potent antifouling compounds are brominated tyrosine derivatives that 
have cationic guanidine or guanidine-like groups [42]. Nevertheless, no inhibition of biofilm 
formation by Staphylococcus epidermidis was found at 100 µM.  
3. Materials and Methods  
3.1. Animal Material 
Figure 3. The structurally related compounds Securidine A (1), Pulmonarin (2), and Synoxazolidinone
B (3).
The effect of Securidine A (1) against P l exa ined, since PTP-1B is regar ed s a
promising target for the treatment of diabet s [41]. However, no inhibition of PTP-1 at
50 µM or 100 µM. Many potent antifouling comp unds are brominated tyrosine derivatives that have
cationic guanidine or guanidine-like groups [42]. Nevertheless, no inhibition of biofilm formation by
Staphylococcus epidermidis was found at 100 µM.
3. Materials and Methods
3.1. Animal Material
The marine bryozoan Securiflustra securifrons (Palllas, 1766) was collected by an Agassiz trawl at
73 m depth from west Spitzbergen (71.0759◦ N, 24.4355◦ E) in April 2014. The fresh sample weighed
336.01 g and was frozen immediately at −23 ◦C. The specimen was identified by Norwegian marine
biobank Marbank (Institute of Marine Research, Tromsø, Norway) and they have a taxonomical
reference sample in their collection. The sample was stored at −23 ◦C until further processing.
Molecules 2017, 22, 1236 6 of 11
3.2. Extraction
The lyophilized animal material was ground and extracted twice with ultrapure water (Milli-Q;
Millipore, Billerica, MA, USA) at 4 ◦C for 24 h in darkness. After centrifugation (4000 rpm at 5 ◦C
for 30 min), the supernatants were pooled and reduced under reduced pressure at 40 ◦C, yielding
24.78 g of aqueous extract. The remaining pellet was freeze-dried and extracted twice with 1:1 v/v
of dichloromethane (Merck, Darmstadt, Germany) and methanol (MeOH; Sigma-Aldrich, Steinheim,
Germany) at 4 ◦C. The combined organic extract was subsequently filtered through a Whatman No. 3
filter paper (Little Chalfont, UK) and concentrated under reduced pressure, affording 5.13 g of organic
extract. Both extracts were stored at −23 ◦C until further use. Aqueous extract was used for isolation
of Securidine A (1), in order to avoid including lower polarity molecules in the purification process.
3.3. Isolation and Purification of Compound 1
An aliquot of the lyophilized aqueous extract (1.5 g) was mixed with 90% MeOH (6–8 mL),
cooled to 4 ◦C, and centrifuged at 4000 rpm and 4 ◦C, in order to precipitate salt. The supernatant
was mixed with 3.0 g resin (Dianon ®HP-20, Supelco Analytical, Bellefonte, PA, USA) and the
mixture was dried by SpeedVac. The dried resin loaded with the aqueous extract was deposited
on top of a column pre-packed with 6.5 g HP20SS, and the extract eluted from the column using a
gradient of H2O/CH3OH/CH3COCH3. The pre-fractionation was performed using a Biotage SP4
chromatography HPFC flash purification system (Biotage, Charlottesville, NA, USA), resulting in
eight fractions. These eight fractions were assayed for cytotoxicity against A2058 melanoma and HT29
colon adenocarcinoma cell lines using the MTS based anticancer assay. Fractions four and five showed
cytotoxic activity and these active fractions were de-replicated using HR-MS. Securidine A (1) was
isolated directly from the aqueous extract by mass guided prep-HPLC.
Isolation of Securidine A (1) was performed by a Waters HPLC purification system. The system
was composed of a 600 pump, a 2996 photodiode array UV detector, a 3100 mass detector and a 2767
sample manager (Milford, MA, USA). The system was controlled with Waters MassLynx version 4.1
and the FractionLynx application manager. The mass of Securidine A (1) (m/z 356.2520) was used as
the collection trigger. The aqueous extract was injected onto a Waters Xterra RP18 (10 mm × 300 mm,
10 µm) HPLC column. Securidine A (1) was eluted with a 10 min with a gradient from 10% to
40% CH3CN (Chromasolv; Sigma-Aldrich) in ultrapure water, both containing 0.1% formic acid
(Pro-analysis, Merck), and the flow rate was 6 mL/min. Further purification was done by Waters
Phenyl-Hexyl Prep (10 mm × 250 mm, 5 µm) HPLC column with a gradient from 10% to 34% of
CH3CN (Chromasolv; Sigma-Aldrich) in ultrapure water with a 10 min and the flow rate of 6 mL/min.
3.4. Structure Determination
UPLC-HR-MS analysis and NMR were used to confirm the structure of Securidine A (1).
UPLC-HR-MS analysis was performed on an Acquity UPLC and a LCT premier Time-of-Fight MS
using ESI+ ionization (Waters). MassLynx version 4.1 was used to process the MS data. The NMR
experiments were acquired on a Bruker Avance III HD spectrometer operating at 599.90 MHz for
protons, equipped with an inverse detected cryo-probe enhanced for 1H, 13C, and 2H. The NMR
samples were prepared by dissolving Securidine A (1) in 500 µL methanol-d3 and transferred into a
5 mm disposable tube. Experiments were typically acquired using gradient selected adiabatic versions
where applicable. All experiments were acquired using Top Spin 3.5 pl2 at 298 K.
3.5. Bioassays
3.5.1. Cytotoxicity
Cell culturing—Human melanoma A2058 (ATCC-CRL-1114 TM, Manassas, VA, USA) and human
colon adenocarcinoma HT29 (ATCC HTB-38 TM) were grown in Dulbecco’s Modified Eagle Medium
(DMEM) (Life technologies TM, city, UK) and Roswell Park Memorial Institute (RPMI)–1640 medium
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(Biochrome GmbH, Germany) respectively. Both media were supplemented with fetal bovine serum
(10%), gentamycin (10 mg/ml), and L-alanyl-L-glutamine (200 mM). Human breast cancer MCF7
(ATCC HTB-22 TM) cells were grown in Eagle’s Minimum Essential Medium (E-MEM) (Biochrom,
GmbH, Berlin, Germany) supplemented with fetal bovine serum (10%), gentamycin (10 mg/mL),
non-essential amino acid without L-alanyl-L-glutamine, sodium pyruvate (100 mM), and sodium
bicarbonate (7.5% w/v). The supplements were purchased from Biochem, GmbH, Berlin, Germany.
All cells were incubated at 37 ◦C with 5% CO2 and 95% air. Cells were sub-cultured with fresh
medium every three to four days. The test concentrations (50 µM and 100 µM) were prepared from the
stock solution of pure compound (10 mg/mL in 100% DMSO) which is dissolved in supplemented
RPMI-1640 medium.
Cell viability was tested against three adherent cancer cell lines, human melanoma A2058,
human colon adenocarcinoma HT29, and human breast cancer MCF7 cell lines in vitro, using an MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt]
colorimetric method. The growing cells were suspended in 100 µL of supplemented medium seeded
at a density of 2000 cells/well in a 96-well microtiter plates (Nunclon TM Delta Surface, Thermo Fisher
Scientific, Denmark). The cells were incubated at 37 ◦C for 24 h. After removal of old medium, the cells
were treated with 50 µM and 100 µM of Securidine A (1). After 72 h incubation, 10 µL of Cell titer 96 ®
Aqueous One Solution Reagent (Promega, Madison, WI, USA) was added to each well and the plates
were incubated for 1 h. The absorbance readings at 485 nm was measured using DTX 880 multimode
detector (Beckman coulter, CA, USA). Cells with RPMI-1640 medium were used as negative control
and cells treated with Triton® X-100 (Sigma-Aldrich, Steinheim, Germany) as positive control. Growth
inhibition was measured by optical density (OD) and was calculated as: Cell survival (%) = (Average
of parallels − positive control)/(negative control − positive control) × 100
3.5.2. Antibacterial Assay
Test strains and culture media—The antibacterial activity of Securidine A (1) was determined
by using a minimum inhibitory concentration (MIC) assay against Staphylococcus aureus (ATCC
25923), Escherichia coli (ATCC 25922), Enterococcus faecalis (ATCC 29212), Pseudomonas aeruginosa (ATCC
27853), and Streptococcus agalactiae (ATCC 12386). Antibacterial test was performed in sterile Muller
Hinton broth (Becton Dickinson, Sparks, MD, USA) and brain heart infusion broth (Becton Dickinson).
The bacterial cultures were obtained from the stock (−80 ◦C) and were grown on blood agar (acquired
from the University hospital, UiT, Tromsø, Norway) at 37 ◦C for 24 h and working bacterial stock culture
were maintained at 4 ◦C. An overnight culture of each strain was prepared and 2 mL of overnight
culture was inoculated in 25 mL of growth media and incubated at 37 ◦C on the shaker at 180 rpm,
until the culture reaches the turbidity according to 0.5 McFarland standard (1.0 × 108 colony forming
unit (CFU)/mL). In this study, bacterial cultures were diluted in 1:100 and then 1:10 in growth media
and the final concentration of bacterial cells in the wells were adjusted to 0.5–3.0 × 105 (CFU)/mL
of S. aureus, E. coli, E. faecalis, and Streptococcus agalactiae and 3.0–7.0 × 104 CFU/mL of P. aeruginosa.
Test concentrations (50 µM and 100 µM) were prepared from the stock solution of Securidine A (1)
(10 mg/mL in 100% DMSO), and was dissolved in MilliQ water.
From the test concentrations, 50 µL was transferred into a 96-well microtiter plate (NunclonTM
Delta Surface, Thermo Fisher Scientific, Denmark). Subsequently, 50 µL of final concentration of
bacterial cells were added and incubated at 37 ◦C for 24 h. After incubation, the activity was measured
as absorbance at 600 nm in a plate reader (1420 Victor3 TM multilabel counter, PerkinElmer®, Singapore)
and WorkOut 2.0 software (Dazdaq Ltd, Brighton, UK) was used for plate reading. Bacterial suspension
with MilliQ water was used as positive control and growth medium with MilliQ water as negative
control. Gentamycin (Amresco, OH, USA) was used as the reference control of this assay. The inhibition
was evaluated by the average of parallel OD value. The OD value ≤0.05 considered as active and
≥0.09 was considered inactive.
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3.5.3. Protein Tyrosine Phosphatase 1B Assay
Reagents—(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Sigma-Aldrich,
Steinheim, Germany), sodium chloride (NaCl; Sigma-Aldrich), dithiothreitol (Sigma-Aldrich),
ethylene diamine tetra-acetic acid disodium salt dehydrate (EDTA; Sigma-Aldrich), bovine
serum albumin (Sigma Aldrich), human recombinant protein tyrosine phosphatase 1B enzyme
(PTP1B; Merck-Calbiochem, Darmstadt, Germany), protein tyrosine phosphatase inhibitor IV
(Merck-Calbiochem), 6,8-difluoro-4-methylumbelliferylphosphate (DiFMUP; VWR, Leuven, Belgium).
The test concentration (10 µM and 50 µM) was obtained from stock solution (10 mg/mL in 100%
DMSO) of Securidine A (1) and was dissolved in the assay buffer.
PTP1B activity of Securidine A (1) was measured in the presence of human recombinant PTP1B
enzyme, flurogenic substrate DiFMUP, and the buffer solution in black polystyrene 96-well microtiter
plate (FluoroNuncTM MaxiSorp Surface, Capital Scientific, TX, USA). The final volume of the mixture
was 100 µL in each well. Each well contained 25 µL of buffer solution (pH 7.2) (25 mM HEPES, 50 mM
NaCl, 2 mM dithiothreitol, 2.5 mM EDTA and 0.01 mg/mL bovine serum albumin), 25 µL of Securidine
A (1), and 50 µL of PTP1B enzyme (31.2 ng/mL). Then, the plate was incubated at 37 ◦C. After 30 min
incubation, 25 µL of 10 µM fluorogenic substrate DiFMUP was added into wells and incubated again
at 37 ◦C for 10 min. The inhibition of enzyme activity was measured as the intensity of fluorescence at
360 nm excitation and 465 nm emission wavelengths by using DTX 880 Multimode detector (Beckman
coulter, CA, USA). The assay buffer was used as the positive control and protein tyrosine inhibitor
IV (160 µM) was used as the negative control. The inhibition of enzyme activity was measured from
the fluorescence and calculated with positive and negative control. The inhibition of enzyme activity
was expressed in percentage and the activity lower than 30% was considered active. The inhibition
of enzyme activity was calculated by (Average of triplicates − negative control)/(positive control −
negative control) × 100.
3.5.4. Biofilm Assay
Test strains—The test strains Staphylococcus epidermidis (RP62A-42-77 ATCC-35984) and
Staphylococcus haemolyticus (Clinical isolate 8-7A) from the stock were grown on blood agar (acquired
from University hospital, UiT, Tromsø) at 37 ◦C for 24 h and these working bacterial stock were
maintained at 4 ◦C.
The bacterial strain S. epidermidis was used to test the biofilm formation on the polystyrene
96-well microtiter plate (Nunclon TM Delta Surface, 734-2097, Thermo Fisher Scientific, Denmark).
The overnight culture was grown in 5 mL of sterile tryptic soy broth (TSB; Merck, Darmstadt, Germany)
in a shaking incubator at 37 ◦C and diluted in 1:100 in TSB medium with 1% of glucose (Sigma-Aldrich).
Securidine A (1) from the stock (10 mg/mL) was dissolved in the MilliQ water, to prepare 100 µM test
concentration. From the test concentration, 50 µL was transferred into the wells, subsequently the
diluted test strain 50 µL was added and incubated at 37 ◦C for overnight. S. epidermidis with sterile
MilliQ water was used as positive, S. haemolyticus with sterile MilliQ water was used as negative
control and medium, with sterile MilliQ water used as blank.
The biofilm formation in the well was determined by using crystal violet (Merck) staining.
The bacterial suspension was removed carefully on the cell paper and the plate was gently washed
with tap water two or three times. After the biofilm fixation was done at 65 ◦C for 1 h, the cells were
stained with 70 µL 0.1% of crystal violet. After 10 min incubation, the crystal violet was removed
carefully on the cell paper and the plate was washed with tap water two or three times. The plate was
dried at 65 ◦C for 1 h and 70 µL 70% ethanol (VWR) was added into the wells. Thereafter, the microtiter
plate was placed on a shaker for 5–10 min. The inhibition of biofilm was assessed by using in the
Victor3 TM multilabel counter at 600 nm and measuring the optical density (OD). If the inhibition of
biofilm rate was 0.25 or lower the OD value was considered active.
Molecules 2017, 22, 1236 9 of 11
4. Conclusions
The new brominated tyrosine derivative Securidine A (1) was isolated from the aqueous extract
of the marine bryozoan Securiflustra securifrons. The structure was determined by interpretation of data
from 1D and 2D NMR experiments and mass spectrometry analysis. In this study, Securidine A (1) did
not show any significant biological activities in the applied bioassays. Further bioactivity profiling is
required in order to identify any potential biological activities of the molecule.
Supplementary Materials: Supplementary data S1–S6 (1H, 13C, HSQC, HMBC, H2BC, COSY and ROESY NMR
spectral data of isolated compound) associated with this article can be found online.
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